Recommended Initial Treatment for Primary Pulmonary Myxoid Sarcoma
Complete surgical resection is the recommended initial treatment for primary pulmonary myxoid sarcoma, as this low-grade sarcoma has excellent prognosis with surgery alone and no evidence supports routine adjuvant chemotherapy or radiotherapy.
Surgical Approach
The treatment paradigm for primary pulmonary myxoid sarcoma (PPMS) differs substantially from other soft tissue sarcomas due to its unique biology and behavior:
- Complete resection with negative margins is the definitive treatment 1, 2, 3, 4
- Wedge resection, lobectomy, or bilobectomy should be performed depending on tumor location and size 5
- Video-assisted thoracoscopic surgery (VATS) can be utilized for peripheral lesions 1
- The goal is R0 resection (complete microscopic clearance), as completeness of resection is the only factor significantly correlated with survival in pulmonary sarcomas 5
Why Surgery Alone?
PPMS is a low-grade malignant tumor with distinctive characteristics that make it amenable to surgical cure:
- Multiple case reports demonstrate excellent outcomes with surgery alone, with patients remaining disease-free for 12-38 months without adjuvant therapy 1, 2, 3, 4
- The tumor harbors characteristic EWSR1-CREB1 (or rarely EWSR1-ATF1) fusion genes, confirming its distinct biology 1, 2, 3, 4
- Unlike high-grade sarcomas, PPMS shows indolent behavior with low metastatic potential when completely resected
When to Consider Systemic Therapy
While surgery is primary treatment, systemic therapy follows general soft tissue sarcoma guidelines only in specific scenarios:
Unresectable or metastatic disease:
- First-line: Single-agent doxorubicin (standard) 6, 7
- Alternative: Doxorubicin plus ifosfamide if higher response rate needed and performance status is good 6, 7
- Second-line options: Ifosfamide, trabectedin, or gemcitabine-based combinations 7
Important caveat: There is no evidence that adjuvant chemotherapy or radiotherapy improves outcomes after complete resection of PPMS 1, 2, 3, 4. The general sarcoma guidelines 6, 7 apply to advanced/metastatic disease, not to completely resected low-grade tumors like PPMS.
Critical Diagnostic Confirmation
Before proceeding with treatment, confirm the diagnosis through:
- Fluorescence in situ hybridization (FISH) for EWSR1 gene rearrangement 1, 2, 3, 4
- DNA sequencing to identify specific fusion partners (CREB1 or ATF1) 3, 4
- Histology alone is insufficient—molecular confirmation is mandatory as PPMS can mimic inflammatory myofibroblastic tumor, extraskeletal myxoid chondrosarcoma, or angiomatoid fibrous histiocytoma 2, 8
Follow-Up Strategy
After complete resection:
- Clinical evaluation and cross-sectional imaging (CT chest) every 3-6 months initially 7
- Extend to annual imaging after 5 years 7
- No routine adjuvant therapy required for completely resected disease 1, 2, 3, 4
- Consider repeat resection for isolated recurrences 5
Common Pitfalls to Avoid
- Do not reflexively apply aggressive sarcoma protocols to this low-grade tumor—PPMS behaves differently from high-grade soft tissue sarcomas
- Do not administer adjuvant chemotherapy after complete resection without evidence of benefit
- Do not rely on histology alone—molecular confirmation with EWSR1 rearrangement is essential for accurate diagnosis 1, 2, 3, 4
- Ensure complete resection with negative margins, as positive margins significantly worsen prognosis 5